SCITECH DEVELOPMENT

SCITECH at a glance

Drug Product

ST-001 nanoFenretinide (Proprietary Formulation)
= Fenretinide + SDV.

 

Drug Target

2 cancer indications: t-cell lymphoma; and,
small cell lung cancer (SCLC);
All diseases with limited therapeutic options.

 

Proven Anti-Cancer Drug
Fenretinide has established efficacy in humans;
shown to be safe in 1,000’s of patients.

 

Unique ST-001 nanoFenretinide Formulation
Patented;
Drug delivery of therapeutic doses - safely & effectively.

 

Strategic & Rapid Drug Development
Existing human efficacy data;
Access to NCI data;
Streamlined clinical trials design;
Fenretinide provided free by NCI.

FDA expedited programs anticipated:
(1) Fast Track designation
(2) FDA Orphan Drug designation - Granted Dec. 2017
(3) Accelerated Approval pathway
(4) Priority Review designation.

 

Amount of Financing Sought
$15MM Series A for completion of clinical trials required for NDA filing.

 

Use of Funds
cGMP drug manufacture (ST-001) Clinical Trials (Phase I);
FDA compassionate use approval & NDA filings.

 

Exit Strategy
Targeted acquisition.

 

Time to Market
2-3 years (unusually short).

Drug Mechanism of Action (MOA)

ST-001 NanoFenretinde Drug MOA (YouTube video)
 

 

CONNECT

LinkedIn
Facebook
YouTube
Twitter - #SciTechUSA - SciTech Develop
Instagram
SlideShare
Pinterest - SciTech Development

For investment and partnering opportunities contact:

Earle Holsapple  | 

© 2017-2019 SciTech Development LLC